Eton Pharmaceuticals, Inc. (NasdaqGM: ETON)
Health Care · Pharmaceuticals · US
$61.60
-2.30% today · +268.9% 1Y
Eton Pharmaceuticals, Inc. (NasdaqGM: ETON) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.80B and employs 44 people.
Over the last twelve months the share price has gained 268.9%, trading between 14.27 and 66.37.
Tweenvest scores Eton Pharmaceuticals, Inc. across four factors: quality 63/100, value 12/100, growth 100/100. Its strongest factor is growth.
ETON price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.80B
- Revenue (TTM)
- $105.59M
- P/E
- 147.31
- EPS
- 0.43
- Dividend yield
- —
- Beta (5Y)
- 0.87
- 52-week high
- $66.37
- 52-week low
- $14.27
- Avg volume (3M)
- —
- Shares outstanding
- 28.58M
- Employees
- 44
- Next earnings
- —
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
- ISIN
- US29772L1089
- Founded
- 2017
- Listed since
- Nov 14, 2018
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,215.72 | -1.45% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $271.68 | -0.53% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $154.48 | -1.26% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.20 | -1.50% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.46 | -1.84% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.33 | -0.86% |
Figures last refreshed Aug 18, 2026.